Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DNA X, Inc.SONM · Entity 8261 | Director | November 18, 2022 | November 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DNA X, Inc.
Report date November 18, 2022 · Filed November 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 149,426 |
Reported balance
After 2022-11-18 transaction · row 1
1 source rowRow 1 · 2022-11-18 · Grant · Acquired 47,732 · Balance 149,426 F1: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of Sonim Technologies, Inc. (the "Issuer") or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of Sonim Technologies, Inc. (the "Issuer") or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2022 Filed Nov 22, 2022 02:45 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 47,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-033221 · ownership.xml · nonDerivative · entry 1 Principe Jose Carlos · CIK 0001941316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,426 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of Sonim Technologies, Inc. (the "Issuer") or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 23:10 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 85,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-021814 · ownership.xml · nonDerivative · entry 1 Principe Jose Carlos · CIK 0001941316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,714 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of Sonim Technologies, Inc. (the "Issuer") or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 05, 2022 Filed Oct 14, 2022 20:06 UTC Amendment | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 101,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-028458 · ownership.xml · nonDerivative · entry 1 Principe Jose Carlos · CIK 0001941316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,694 F1 · shares: The Reporting Person's previously filed Form 4 inadvertently (i) understated the number of shares of common stock of Sonim Technologies, Inc. (the "Issuer") disclosed in Columns 4 and 5 by 15,980 shares due to a mathematical error in the calculation of the value of shares for the purpose of issuance and (ii) incorrectly described the vesting schedule of issued restricted stock units (the "RSUs"). The RSUs vest in three equal annual installments on the anniversary date on which the Reporting Person was appointed as a director of the Issuer's board, subject to continuous service on each vesting date. This Form 4 corrects the above-described errors by increasing the number of shares and the total amount of securities beneficially owned by the Reporting Person. F1 · balance_after: The Reporting Person's previously filed Form 4 inadvertently (i) understated the number of shares of common stock of Sonim Technologies, Inc. (the "Issuer") disclosed in Columns 4 and 5 by 15,980 shares due to a mathematical error in the calculation of the value of shares for the purpose of issuance and (ii) incorrectly described the vesting schedule of issued restricted stock units (the "RSUs"). The RSUs vest in three equal annual installments on the anniversary date on which the Reporting Person was appointed as a director of the Issuer's board, subject to continuous service on each vesting date. This Form 4 corrects the above-described errors by increasing the number of shares and the total amount of securities beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.